ONMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ONMD is not a good buy right now for an impatient trader. Despite a +4.81% pre-market bounce to 0.828, the technical setup remains bearish (negative/expanding MACD) and the near-term pattern-based outlook skews slightly negative over the next week/month. Without a proprietary buy signal or clear company-specific catalyst, the risk/reward is unfavorable at this moment.
Trend/Setup: Bearish-to-weak. The MACD histogram is -0.0022 (below zero) and negatively expanding, signaling downside momentum is still building. RSI(6) is 26.27, which is near oversold territory, consistent with a possible short-term bounce but not a confirmed reversal. Moving averages are converging, suggesting consolidation rather than a clean uptrend. Key levels: Current pre-market price (0.828) is below the pivot (0.902), which keeps the bias weaker until reclaimed. Support levels sit at S1 0.758 and S2 0.67; a break below 0.758 increases the odds of a quick move toward 0.67. Resistance is at the pivot 0.902, then R1 1.045. Probabilistic trend (pattern analogs): ~+1.44% next day (coin-flip odds), but -1.23% next week and -3.01% next month, arguing against chasing the pre-market strength.
Intellectia Proprietary Trading Signals
Pre-market strength (+4.81%) may reflect short-term dip-buying interest.
Sector/news tone is positive for medical imaging and AI diagnostics overall (growing market demand), which can be a thematic tailwind, though the provided items appear not clearly company-specific to ONMD.
Hedge fund and insider activity are neutral (no notable recent selling pressure indicated by the dataset).
Bearish momentum signal (MACD negative and expanding) and price remains below the key pivot (0.902).
Pattern-based outlook implies mild downside bias over 1-week and 1-month horizons.
No proprietary Intellectia buy signals today (removes a key reason to buy immediately).
No identifiable, clearly ONMD-specific event-driven catalyst in the provided news summary.
Latest reported quarter: 2025/Q3. Revenue rose to $177K (+24.65% YoY), but profitability remains weak: Net income fell to -$741K (63.99% worse YoY) and EPS declined to -0.01 (85.71% worse YoY). Gross margin is still negative (reported -125.42), despite an improvement YoY. Overall: growth off a very small revenue base while losses deepened—fundamentals do not yet support a confident buy-now stance.
No analyst rating/price target change data was provided, so no recent Wall Street upgrades/downgrades or target revisions can be confirmed. Pros view (inferred from data): revenue growth and positive thematic backdrop in imaging/AI. Cons view: ongoing losses, negative margins, and weak technical momentum; lack of clear institutional/insider conviction signals and no noted catalysts. Politician/congress activity: No recent congress trading data available.
